SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 2007; 46: 894921.
  • 2
    Fliers EA, Franke B, Buitelaar JK. [Hereditary factors in attention deficit hyperactivity disorder]. Ned. Tijdschr. Geneeskd. 2005; 149: 17261729.
  • 3
    Brinkman WB, Sherman SN, Zmitrovich AR et al. Parental angst making and revisiting decisions about treatment of attention-deficit/hyperactivity disorder. Pediatrics 2009; 124: 580589.
  • 4
    Gau SS, Chen SJ, Chou WJ et al. National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. J. Clin. Psychiatry 2008; 69: 131140.
  • 5
    Biederman J, Petty CR, Dolan C et al. The long-term longitudinal course of oppositional defiant disorder and conduct disorder in ADHD boys: Findings from a controlled 10-year prospective longitudinal follow-up study. Psychol. Med. 2008; 38: 10271036.
  • 6
    Gittelman R, Mannuzza S, Shenker R, Bonagura N. Hyperactive boys almost grown up. I. Psychiatric status. Arch. Gen. Psychiatry 1985; 42: 937947.
  • 7
    Zametkin AJ, Borcherding BG. The neuropharmacology of attention-deficit hyperactivity disorder. Annu. Rev. Med. 1989; 40: 447451.
  • 8
    Jensen PS, Arnold LE, Swanson JM et al. 3-year follow-up of the NIMH MTA study. J. Am. Acad. Child Adolesc. Psychiatry 2007; 46: 9891002.
  • 9
    Pelham WE, Gnagy EM, Burrows-Maclean L et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001; 107: E105.
  • 10
    Swanson JM, Wigal SB, Wigal T et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics 2004; 113: e206e216.
  • 11
    Coghill D, Seth S. Osmotic, controlled-release methylphenidate for the treatment of ADHD. Expert Opin. Pharmacother. 2006; 7: 21192138.
  • 12
    Kim Y, Shin MS, Kim JW, Yoo HJ, Cho SC, Kim BN. Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD. Hum. Psychopharmacol. 2009; 24: 95102.
  • 13
    Chou WJ, Chou MC, Tzang RF et al. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes. Psychiatry Clin. Neurosci. 2009; 63: 167175.
  • 14
    Hoare P, Remschmidt H, Medori R et al. 12-month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH. Eur. Child Adolesc. Psychiatry 2005; 14: 305309.
  • 15
    Buitelaar J, Medori R. Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: A review of the potential benefits of long-acting stimulants. Eur. Child Adolesc. Psychiatry 2009; 19: 325340.
  • 16
    Lee SI, Hong SD, Kim SY et al. Efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007; 31: 210216.
  • 17
    Steinhoff KW. Special issues in the diagnosis and treatment of ADHD in adolescents. Postgrad. Med. 2008; 120: 6068.
  • 18
    Rader R, McCauley L, Callen EC. Current strategies in the diagnosis and treatment of childhood attention-deficit/hyperactivity disorder. Am. Fam. Physician 2009; 79: 657665.
  • 19
    Steele M, Jensen PS, Quinn DM. Remission versus response as the goal of therapy in ADHD: A new standard for the field? Clin. Ther. 2006; 28: 18921908.
  • 20
    Frank E, Prien RF, Jarrett RB et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch. Gen. Psychiatry 1991; 48: 851855.
  • 21
    Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can. J. Clin. Pharmacol. 2006; 13: e50e62.
  • 22
    Pan XX, Ma HW, Wan B, Dai XM. [Effectiveness of oral osmotic-methylphenidate in treatment of attention deficit hyperactivity disorder in children]. Zhongguo Dang Dai Er Ke Za Zhi 2008; 10: 471474.
  • 23
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder. American Psychiatric Press, Washington, DC, 2000.
  • 24
    Liu YC, Liu SK, Shang CY, Ch L, Tu C, Gau SS. Norm of the Chinese Version of the Swanson, Nolan, and Pelham, version IV scale for ADHD. Taiwanese J. Psychiatry 2006; 20: 290304.
  • 25
    Gau SS, Cheng TA, Soong WT. Adolescent psychopathology and social functioning. In: The 3rd congress of Asian Society for Child and Adolescent Psychiatry and Allied Professions. ASCAPAP, Taipei, 2003; 89.
  • 26
    Jensen PS, Hinshaw SP, Swanson JM et al. Findings from the NIMH Multimodal Treatment Study of ADHD: Implications and applications for primary care providers. J. Dev. Behav. Pediatr. 2001; 22: 6073.
  • 27
    Gau SS, Shen HY, Chou MC, Tang CS, Chiu YN, Gau CS. Determinants of adherence to methylphenidate and the impact of poor adherence on maternal and family measures. J. Child Adolesc. Psychopharmacol. 2006; 16: 286297.
  • 28
    Faraone SV, Biederman J, Zimmerman B. An analysis of patient adherence to treatment during a 1-year, open-label study of OROS methylphenidate in children with ADHD. J. Atten. Disord. 2007; 11: 157166.
  • 29
    Safren SA, Duran P, Yovel I, Perlman CA, Sprich S. Medication adherence in psychopharmacologically treated adults with ADHD. J. Atten. Disord. 2007; 10: 257260.
  • 30
    Thiruchelvam D, Charach A, Schachar RJ. Moderators and mediators of long-term adherence to stimulant treatment in children with ADHD. J. Am. Acad. Child Adolesc. Psychiatry 2001; 40: 922928.
  • 31
    MacNaughton KL, Rodrigue JR. Predicting adherence to recommendations by parents of clinic-referred children. J. Consult. Clin. Psychol. 2001; 69: 262270.
  • 32
    Hechtman L, Abikoff H, Klein RG et al. Academic achievement and emotional status of children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J. Am. Acad. Child Adolesc. Psychiatry 2004; 43: 812819.
  • 33
    Swanson J, Gupta S, Lam A et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: Proof-of-concept and proof-of-product studies. Arch. Gen. Psychiatry 2003; 60: 204211.